Press Release

Press Release | Apr 07, 2021

Bonafide, the company pioneering mainstream medical use of drug-free, naturally derived health solutions for menopause, announces today that Dr. Alyssa Dweck will join its team as its Chief Medical Officer. Bonafide’s products are already trusted by over 9,000 unpaid health care professionals – primarily OBGYNs –  and 70,000+ women.

Press Release | Mar 30, 2021

Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it has expanded its capabilities to address the orthoplastics market by incorporating its recently introduced Sequel line of external fixators to complement its existing wound debridement and regenerative products

Press Release | Mar 23, 2021

Aktana, the global leader in intelligent customer engagement for the life sciences industry, announced the release of a dedicated configuration of their AI offering tailored to the needs of emerging and mid-sized biopharma companies. The new Aktana contextual intelligence offering provides commercial teams at any sized organization with the right insights and content at the

Press Release | Mar 15, 2021

Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) is pleased to announce that its common shares have been approved for listing and trading in U.S. dollar currency on the NASDAQ Stock Market LLC (“NASDAQ”). Trading on the NASDAQ will commence at the start of trading on March 16, 2021 under the symbol “GBNH”. Greenbrook’s

Press Release | Mar 04, 2021

Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it has received a Health Canada license for the neXus® Ultrasonic Surgical System. This approval confirms that neXus meets the requirements of Health Canada, allowing Misonix to commercialize neXus, along with

Press Release | Mar 01, 2021

Nutrition21, LLC (“Nutrition21“) has announced the launch of its latest ingredient, Lustriva™, a clinically tested beauty-from-within ingredient that contains Bonded Arginine Silicate (arginine silicon inositol complex) and Magnesium Biotinate (Nutrition21’s proprietary biotin formulation). The latter is a unique combination that significantly increases biotin solubility 40 times more compared to standard D-biotin, which is commonly found

Press Release | Mar 01, 2021

Colorescience®, a leading dermatologist-recommended specialty skincare and cosmetics company, is pleased to announce an expansion of its best-selling Even Up® line of hyperpigmentation products.  New Even Up® Multi-Correction Serum ($89) features patented, clinically-proven Lumira® brightening complex to minimize the appearance of discoloration.  The addition of a novel peptide and lipid blend and powerful hydrating ingredients result in

Press Release | Feb 25, 2021

Interpace Biosciences, Inc. (“Interpace” or “the Company”), today announced that Blue Cross Blue Shield of Illinois, owned by Health Care Services Corporation (HCSC) and the largest health plan in Illinois with greater than 8 million covered lives, has entered into an agreement to provide both coverage and in-network status for Interpace’s molecular combination thyroid tests,

Press Release | Feb 24, 2021

Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the requirements for trading of the Company’s common stock on the OTCQX® Best Market (“OTCQX”) and will begin trading on OTCQX at the open of the market on February

Press Release | Feb 18, 2021

Restorative Therapies, Inc – the leading provider of innovative, integrated therapeutic medical devices that are the standard of care in rehabilitation therapy for many neurological conditions – announced today the launch of Xcite2. Xcite2 was designed to allow clinicians to easily and efficiently apply multi-channel FES with task specific activities commonly completed in therapy. The device

Press Release | Feb 15, 2021

Verogen Inc. announced today that it is expanding capabilities for the NDIS-approved MiSeq FGx Sequencing System with the commercial launch of the ForenSeq Kintelligence Kit, a solution optimized for low input and degraded samples. The kit targets 10,230 forensically curated SNPs, alleviating genetic privacy concerns by minimizing medically informative markers. The seamless integration of this workflow

Pages 1 2 3 4 5 12